Cadmium is a non-essential metal, a stable and persistent toxicant that is continuously introduced into the environment through the processing of metal ores and the burning of fossil fuels ([@bib8]; [@bib16]; [@bib20]; [@bib37]; [@bib4]). It is well established that cadmium causes both acute and chronic cytotoxicity. Significant correlations between chronic cadmium exposure and the risk of human colon, breast, lung and prostate cancer have been reported ([@bib36]; [@bib49]; [@bib29]). The precise molecular mechanisms by which this metal causes healthy cells to transform to malignant states however, have yet to be fully defined. Current models propose the induction of reactive oxygen species, impairment of DNA repair, inhibition of p53 signalling, alterations in the Bcl2/Bax ratio and silencing the pro-apoptotic function of caspase cascades may contribute to cadmium-induced prostate carcinogenesis ([@bib15]; [@bib43]; [@bib3]; [@bib6]).

*In vitro* studies demonstrated that normal human prostate epithelial cells (RWPE-1) when chronically exposed to cadmium, transformed to malignant cells (cadmium-transformed prostate epithelial; CTPE). The transformation of RWPE-1 cells was confirmed using cellular and molecular markers of cancer phenotypes including adenocarcinoma formation in nude mice ([@bib2]; [@bib64]; [@bib9]). Several potential processes that may contribute to cadmium-induced prostate carcinogenesis; including cell proliferation and differentiation, cell cycle progression, DNA synthesis and repair, apoptosis and other cellular activities; have been identified using RWPE-1 and CTPE cells ([@bib11]; [@bib1]; [@bib3]; [@bib10]; [@bib21]; [@bib6]). Additionally, intracellular signalling pathways including mitogen-activated protein kinase, phosphatidylinositol-3-kinase (PI3K), AKT, Nuclear Factor-*κ*B (NF*κ*B), p53 inactivation and induction of epithelial--mesenchymal transition (EMT) may contribute to cadmium-induced prostate carcinogenesis have been characterised using these cell lines ([@bib1], [@bib2], [@bib3]; [@bib41]; [@bib62]).

The involvement of autophagy, the lysosomal-mediated degradation of damaged organelles, in cadmium-induced carcinogenesis is currently being explored ([@bib39]; [@bib50]; [@bib13]). The induction of autophagy involves many steps to initiate autophagosome formation, which eventually promotes autolysosomal degradation through the activation of the cytosolic microtubule-associated protein 1A/1B-light chain 3A (LC3A) ([@bib24]; [@bib26]; [@bib31]). LC3A can then be converted to LC3B through the processing by Atg7, an E1-like activating enzyme ([@bib67]). Cytosolic LC3B is recruited to the membrane of the phagophore to assist in the formation of the autophagosomes, which are required for induction of cell death. The lysosomal protein Placental Specific 8 (Plac8) is currently being examined as an effector in cellular transformation through autophagy. Plac8 facilitates autophagosome--lysosome fusion by activating pro-survival function of autophagy ([@bib35]). Plac8 localises to the lysosomal membrane where it binds to the lysosomal proteins LAMP-1 and -2, which are essential for autolysosomal initiation ([@bib35]).

It is well established that cadmium exposure is a risk factor for human prostate carcinogenesis; the second leading cause of cancer death in United States and worldwide ([@bib61]). Effectively preventing this disease requires the identification of novel compounds. Natural products have been shown to be chemopreventive candidates for prostate cancer ([@bib66]; [@bib25]; [@bib7]; [@bib45]; [@bib63]; [@bib33]). One such product is Psoralidin (Pso), isolated from the seeds of the medicinal pant *Psoralea corylifolia* (Leguminosae) ([@bib68]). Psoralidin induces cytotoxicity in various cancers and may have anti-inflammatory, antioxidant and antitumour effects ([@bib40]; [@bib53]; [@bib58]; [@bib17]; [@bib28]).

In this study, the mechanism by which Pso effectively inhibits oncogenic autophagy and promotes cell death in CTPE cells both *in vitro* and *in vivo* was examined. Our results demonstrated that Pso inhibited autophagy flux by Plac8 inhibition and induce apoptosis. In addition, oral administration of Pso inhibited tumour growth of CTPE cells in mice, suggesting that autophagy inhibition may prevent prostate cancer growth.

Materials and methods
=====================

Cell lines and reagents
-----------------------

The normal prostate epithelial cell line RWPE-1 was purchased from the American Type Culture Collection (Manassas, VA, USA). cadmium-transformed prostate epithelial cells were generous gift from Dr Mike Waalkes (NIEHS). Both cell lines were maintained in KSFM medium containing 50 *μ*g ml^−1^ bovine pituitary extract, 5 ng ml^−1^ epidermal growth factor and 1% antibiotic and antimycotic solution in a humidified atmosphere of 5% CO~2~ at 37 °C. 10 *μ*M cadmium (final concentration) was used for *in vitro* studies. The following antibodies were obtained from Cell Signaling Technology (Danvers, MA, USA): cell survival (PI3K p85, p110, p65, Bcl-2), autophagy markers (Plac8, Lamp-1, LC3B, Atg-3, -5, -7, 12, 16L, Beclin) and apoptosis markers (BAX, cleaved caspase-9, -3 and PARP). Beta-actin, Lamin A/C, anti-mouse, anti-goat and anti-rabbit secondary antibodies conjugated with HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). TUNEL kits were purchased from BD Biosciences (San Diego, CA, USA). Alexa Fluor 488 and prolong gold anti-fade with DAPI mount were purchased from Invitrogen (Grand Island, NY, USA).

Cell proliferation and soft agar colony formation assays
--------------------------------------------------------

Cells were treated with various concentrations of Pso in DMSO for 24 h. Cell viability was then measured using MTT assays (Cell Signaling, Danvers, MA, USA), according to the manufacturer\'s protocol and as previously described ([@bib53]; [@bib47]; [@bib54], [@bib56], [@bib57]). Anchorage-independent growth was monitored by colony formation assay using a CytoSelectTM 96-well *in vitro* tumour sensitivity assay kit (Cell Biolabs, Inc., San Diego, CA, USA), per the manufacturer's instructions ([@bib56]).

Apoptosis assay
---------------

Apoptosis assays were performed using terminal deoxynucleotidyl transferase dUTP nick end labelling TUNEL Apoptosis Detection Kits (EMD Millipore, Billerica, MA, USA) as per the manufacture protocol. Briefly, cells were grown on coverslips and then treated with Pso (4 *μ*M) for 24 h. Following this incubation, cells were fixed with paraformaldehyde for 1 h, then permeabilised with 0.1% Triton X-100 and incubated with 50 *μ*l TUNEL reaction mixture. The presence and number of apoptotic cells were determined by confocal microscopy.

Protein extraction and western blotting
---------------------------------------

The CTPE cells were seeded in 6-well plates. After 24 h, cells were incubated with Pso (4 *μ*M) or DMSO (vehicle control) for 12 and 24 h. Whole protein lysates were then prepared using Mammalian Protein Extraction Reagent (Thermo Scientific) according to the manufacturer's protocol. Following gel electrophoresis, western blotting was performed using antibodies against P13K, p65, Plac8, Lamp-1, LC3B, Atg-3, -5, -7, 12, 16L, Beclin, Lamin A cleaved caspase-9, -3 and PARP. Levels of protein expression were measured by chemiluminescence ([@bib47]; [@bib54], [@bib56], [@bib57]). The NIH image J software was used for densitometry analysis.

Real time quantitative PCR
--------------------------

Total RNA was isolated from vehicle and Pso-treated CTPE cells by Qiagen, RNeasy Kit and 1 *μ*g RNA was used for cDNA synthesis using the Applied Biosystems cDNA synthesis kit by using SYBR Green super mix (QIAGEN Inc., Valencia, CA, USA), Quantitative RT-PCR was performed as previously published.

NF*κ*B activation assay
-----------------------

To measure NF*κ*B activation in control and Pso-treated CTPE cells, nuclear extracts were prepared using N-PER-Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific) according to the manufacturer's protocol. The NF*κ*B p65 Transcription Factor Assay Kit (Abcam, Cambridge, MA, USA) was used to detect NF*κ*B activation according to the manufacturer's protocol.

Invasion assays
---------------

The effects of Pso on the invasive properties were determined using Boyden chambers equipped with 8-*μ*m pore size polyethylene terephthalate membranes coated with Matrigel (BD Biosciences, San Jose, CA, USA). Approximately 2 × 10^4^ cells in media with or without Pso were layered over the gel and allowed to migrate for 24. Cells were then stained, visualised and counted.

Wound healing assay
-------------------

Pso-containing medium was added to cells plated in 6-well plates and after reaching confluency. Wounds were generated by scratching with a pipette tip at the base of each well plate. Images were acquired at 0 h and 24 h after wound creation. The distance that cells migrated through the area created by scratching was determined by using NIS-Element AR software (Nikon Instruments Inc., Melville, NY, USA)

Immunofluorescence staining
---------------------------

Cadmium-transformed prostate epithelial cells were seeded onto coverslips and allowed to attach for 24 h. The cells were treated for 24 h with Pso and then fixed and permeabilised. Cells were incubated with primary antibodies to Plac8, LAMP1 or LC3B overnight. After washing, cells were incubated with Alexa Fluor 488- or 594-labelled secondary antibodies for 45 min. and counterstained with DAPI to label nuclei. The presence and locations of Plac8, LAMP1 and LC3B were visualised using immunofluorescence microscopy, as previously described ([@bib47]; [@bib54], [@bib56], [@bib57]).

Xenograft studies
-----------------

All animals were housed under pathogen-free conditions, and experiments were performed in accordance with Institutional Animal Care & Use Committee (IACUC) and approved by University of Louisville. Balb/c athymic nude mice (*nu/nu*) were purchased from The Jackson Laboratory and used at 6 weeks of age. For subcutaneous tumour xenograft studies, CTPE cells approximately (1.5 × 10^5^) in 50-*μ*l (final volume) of phosphate-buffered saline and Matrigel (1 : 1) were injected into separate flanks of mice (*n*=10). Mice were monitored twice weekly and tumour volumes were measured once a week. To measure the ability of Pso to inhibit tumour cell growth, Pso (20 mg kg^−1^) was given orally for 5 days for 4--5 weeks. Control mice were received sesame oil.

For histological examination, tumour samples derived from CTPE and Pso-treated tumour xenografts were examined using light microscopy following fixation staining with hematoxylin and eosin (H&E). Similarly, tumour sections were stained with primary antibodies for Plac8, *β*-catenin and Ki-67 followed by incubation with secondary antibody.

Statistical analysis
--------------------

Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS 15.0 software (IBM SPSS Statistics, IBM, Ehningen, Germany). Differences between treatments groups were analysed either using a two-sample Student's *t*-test for normally distributed variables or the Wilcoxon rank sum test for non-normally distributed variables or one way ANOVA. *P* values below 0.05 were considered to be significant. Data are presented as the mean±s.d. of a minimum of three independent experiments unless stated otherwise. Significant difference from control values was indicated at \**P*=0.05, \*\**P*=0.01 and \*\*\**P*=0.001

Results
=======

Psoralidin inhibits CTPE cell growth and induces apoptosis
----------------------------------------------------------

We explored the anticancer effects of Pso in CTPE cells. To measure levels of cytotoxicity, cells were treated with different concentration of Pso (0--10 *μ*M) for 24 h Psoralidin inhibited CTPE cell growth and proliferation with an IC~50~ value of ∼4 *μ*M. Conversely, Pso did not significantly inhibit normal prostate epithelial cell growth ([Figure 1](#fig1){ref-type="fig"}). These results indicate that Pso specifically targets transformed prostate epithelial cells. The ability of Pso to inhibit CTPE cell growth in soft agar, which is a stringent test for malignant cell transformation, was also determined. Exposure to Pso at concentrations \>4 *μ*M significantly (*P*\<0.01) inhibited the colony forming ability of CTPE cells by almost 2-fold, as compared with vehicle ([Figure 1](#fig1){ref-type="fig"}).

The effect of psoralidin on autophagy in CTPE cells
---------------------------------------------------

Low concentrations of cadmium induce autophagy-promoted cell proliferation in non-transformed cells ([@bib18]). To determine if the growth inhibitory effects of Pso in CTPE cells is mediated by autophagy, changes in protein levels of autophagy markers were measured. In Pso-treated CTPE cells, the steady-state levels of Beclin, Atg-3, -5, 7--12 and -16L increased. The levels of LC3B increased with concomitant time dependent decreases in the expression of Plac8 and LAMP1 ([Figure 2](#fig2){ref-type="fig"}). Psoralidin treatment of CTPE cells lead to significant changes in LC3B and Plac8 mRNA levels, similar to those observed for protein ([Figure 2](#fig2){ref-type="fig"}). A significant difference in LAMP1 mRNA levels was not observed.

Immunofluorescence analysis was used to define changes in the sub-cellular localisation of Plac8, LAMP1 and LC3B associated with Pso treatment in CTPE cells. In untreated cells, low levels of LC3B was observed in cytosol ([Figure 2](#fig2){ref-type="fig"}). Following Pso treatment, the level of Plac8 mRNA decreased similar to the cognate protein level. In contrast, the levels of LC3B appeared as perinuclear puncta, likely associated with autolysosomes and autophagosomes, respectively ([Figure 2](#fig2){ref-type="fig"}). To confirm inhibition of Plac8 blocks the fusion of autophagosome and autolysosome in CTPE cells, we analysed the co-localisation of Plac8 and LC3B in controls, as wells CTPE cells treated with Pso. Control cells exhibited a co-localisation of Plac8 and LC3B, however inhibition of Plac8 prevented autophagosome (Plac8) and autolysosome (LC3B) fusion in Pso-treated CTPE cells which was similar to chloroquine treatment ([Figure 2](#fig2){ref-type="fig"}).

TUNEL assays were performed to determine if the inhibition of cell growth by Pso was due to an induction of apoptosis. Treatment of CTPE cells with 4 *μ*M Pso for 24 h resulted in a significant (*P*\<0.001) increase in the number of TUNEL positive cells, compared to vehicle-treated cells. In addition, time-dependent increases in the levels of the pro-apoptotic BAX protein and caspase cascade proteins; cleaved caspase-9, caspase-3, and poly-ADP ribose polymerase (PARP) were observed in Pso-treated CTPE cells ([Figure 3](#fig3){ref-type="fig"}).

Psoralidin inhibits NF*κ*B signalling in CTPE cells
---------------------------------------------------

Cadmium induces the activity of pro-survival factors, such as NF*κ*B and AP-1 in both cultured cells and animal models ([@bib70]; [@bib19]). The effects of Pso on NF*κ*B and its downstream targets in CTPE cells were determined. Pso significantly inhibited (*P*\<0.05) NF*κ*B binding to its cognate promoter element. There were also significant, time-dependent decreases in the expression of the downstream effector, the anti-apoptotic protein Bcl-2 ([Figure 4A](#fig4){ref-type="fig"}). These results were further confirmed by analysing cytosolic and nuclear fraction of CTPE cells after Pso treatment: downregulation of p65 expression and NF*κ*B activation were seen in the nuclear fraction of CTPE cells ([Figure 4B and C](#fig4){ref-type="fig"}). While analysing upstream of NF*κ*B regulators, Pso treatment inhibited the expression of p85, a catalytic unit of PI3K complex without affecting the total levels of p110 ([Figure 4A](#fig4){ref-type="fig"}).

Inhibition of EMT phenotypes in CTPE cells by Pso
-------------------------------------------------

Earlier studies demonstrated that CTPE cells express increased levels of secreted matrix metalloproteinase-2 (MMP2) and MMP9, which correlated with the invasive phenotype in xenograft models ([@bib2]; [@bib51]). The effect of Pso on EMT phenotypes, invasion and migration, were determined in CTPE cells. Pso significantly (*P*\<0.0001) inhibited invasion of CTPE cells by 2.5-fold, compared to the vehicle-treated control cells using a trans-well invasion assay. In a wound healing migration assay, vehicle-treated CTPE cells exhibited complete wound recovery (∼30%) after 24 h, whereas Pso treatment significantly (*P*\<0.05) inhibited the migration of CTPE cells to 4.6%. The effect of 12 and 24 h Pso treatment on the steady-state levels of EMT proteins E-cadherin, *β*-catenin, Vimentin and MMP9 in CTPE cells were determined by western blot analysis. A time dependent, significant induction of E-cadherin (four-fold) was observed. In contrast, Pso treatment caused significant decreases in the expression of *β*-catenin, Vimentin, and MMP9 ([Figure 4D](#fig4){ref-type="fig"}). The fold change in the steady-state mRNA levels of EMT genes was determined using qRT-PCR. Similar to the protein results, significant increases in E-cadherin with decreases in MMP9 expression were observed following Pso-treatment ([Figure 4E](#fig4){ref-type="fig"}). The levels of *β*-catenin mRNA did not significantly change. Combined these results suggest that Pso may be a potent inhibitor of metastasis.

Oral administration of Pso inhibited CTPE tumour xenograft formation in nude mice
---------------------------------------------------------------------------------

We examined the anti-cancer ability of Pso *in vivo* using the xenograft model. Oral administration of Pso significantly inhibited the tumour growth, compared to vehicle control-treated animals ([Figure 5](#fig5){ref-type="fig"}). No adverse toxic effects were found in any organs of Pso-treated animals and body weights were similar to vehicle-treated mice ([Figure 5](#fig5){ref-type="fig"}).

Histological analysis, H&E staining, of tumours from control and Pso-treated mice showed distinct nuclear and cytosolic components with high intensity in CTPE tumour tissues and induction a high grade mesenchymal component that represented an EMT ([Figure 6](#fig6){ref-type="fig"}). Immunohistochemical examination revealed decreased expression of Plac8 in Pso-treated tumour sections. Decreased numbers of cells expressing the EMT marker *β*-catenin were also seen in Pso-treated animal. A high expression of the cell proliferation marker Ki-67 was observed in sections derived from CTPE tumours from control mice, whereas a decrease in Ki-67 expression was observed Pso-treated animals ([Figure 6](#fig6){ref-type="fig"}, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Reticulocyte staining (angiogenesis marker) revealed increased microvessel formation, indicative of the aggressiveness of CTPE tumour growth in vehicle-treated animals, which was not observed in mice receiving Pso.

Pso treatment caused decreased steady-state mRNA levels of the EMT makers MMP2, MMP9, Snail and *β*-catenin with a significant increase (*P*=0.001) in the epithelial marker E-cadherin ([Figure 6](#fig6){ref-type="fig"}). These results support a role for Pso as a potent compound that inhibits tumour growth.

Discussion
==========

Cadmium is a known human carcinogen and long-term exposure is associated with many cancer types ([@bib36]; [@bib59]; [@bib65]; [@bib30]; [@bib49]; [@bib5]; [@bib27]). In the present study, the chemopreventive effect of Pso, as demonstrated by growth inhibition of CTPE cells *in vitro* and *in vivo,* was shown. The molecular mechanism by which Pso inhibits cadmium-transform prostate cells is associated with inhibition of Plac8, which is responsible for autophagosome and autolysosome fusion and induction of apoptosis.

Consistent with previous results, CTPE cells grow aggressively, compared to the non-transformed parental RWPE-1 cell line, and exhibit malignant phenotypes such as anchor independent growth and mesenchymal characteristics ([@bib14]). At a non-cytotoxic concentration, Pso significantly inhibited the growth and colony forming ability of CTPE cells ([Figure 1](#fig1){ref-type="fig"}). In addition, induction of TUNEL positive cells in Pso-treated CTPE cells suggesting involvement of DNA-damage or fragmentation leading to cell death in CTPE cells.

Published evidence suggests that low concentrations of cadmium induce autophagy-promoted cell proliferation and that higher concentrations induce cell death ([@bib18]). The induction of autophagy-mediated survival mechanism due to lysosome genes ([@bib60]). Recently, ([@bib48]) reported that deletion of Atg7 in Pten-deficient mice ((*Nkx3.1*^*CreERT2*/+^*;Pten*^*F/F*^; *Atg*^Δ/Δ^) caused delayed prostate tumour progression, as well as castration resistant prostate cancer, suggesting that autophagy could be a therapeutic target for prostate cancer. Our findings on global gene arrays showed that the lysosome gene, Plac8 is highly expressed in CTPE cells, compared to RWPE-1 cells (data not shown). In addition, the induction of Plac8 in CTPE cells is responsible for autophagosome/autolysosome fusion that results in cell survival and proliferation. Inhibition of Plac8 by Pso blocks autophagosome/autolysosome fusion which leads to cell death in CTPE cells. Plac8 functions differ in each cell type; overexpression of Plac8 induces apoptosis in human lymphocytes, whereas in fibroblasts it protects cells ([@bib46]; [@bib42]). Plac8 induces EMT in colon cancer cells and cell cycle regulation in pancreatic cancer cells ([@bib38]; [@bib32]). Plac8 also facilitates autophagosome--lysosome fusion by activating the pro-survival function of autophagy in pancreatic cancer ([@bib35]). Plac8 localises to the lysosomal membrane where it binds to the lysosomal proteins Lamp-1 and -2, which are essential for autosomal initiation ([@bib35]). Similarly, in our results downregulation of Plac8 by Pso in cadmium-transformed cells resulted in inhibition of growth in both cell culture and xenograft model of CTPE. In our results the inhibition of Plac8 prevented autophagosome and autolysosome fusion although induction of LC3B activation (RNA, protein and LC3b puncta) were seen in Pso-treated cells. Inhibition of autophagy resulted in induction of cell death in Pso-treated CTPE cells, which is similar to previous findings that accumulation of autophagy vacuoles triggers induction of cell death (apoptosis) without altering mitochondrial membrane ([@bib12]). To support apoptotic induction, we have seen TUNEL positive cells in Pso-treated cells, also confirmed the activation of Caspases and PARP cleavage in CTPE cells suggesting inhibition of autophagy facilitates pro-apoptotic machinery in CTPE cells.

Recently, Son *et al* demonstrated that induction of reactive oxygen species (ROS)-activated PI3K/AKT signalling in cadmium-transformed normal lung epithelial cells (BEAS-2B) ([@bib51]). In our studies, inhibition of NF*κ*B activation and Bcl-2 expression were observed. NF*κ*B activation has been reported in cadmium-transformed cells ([@bib52]; [@bib70]; [@bib19]) and silencing NF*κ*B activation triggers induction of apoptosis in cadmium-treated cells ([@bib69]). Similarly, inhibition of NF*κ*B/Bcl2 and concomitant induction of pro-apoptotic genes BAX and caspase signalling-induced cell death in Pso-treated CTPE cells. The link between PI3K/AKT signalling and oncogenic autophagy is not well defined; however, inhibition of Plac8 and NF*κ*B signalling facilitated cell death in our studies.

We observed that CTPE cells exhibit mesenchymal characteristics and higher constitutive levels of mesenchymal markers, *β*-catenin, MMP2, MMP9 and Snail both *in vivo* and *in vitro*. It's been reported that a higher levels of mesenchymal markers in different cell types treated with cadmium ([@bib14]; [@bib51], [@bib50]). H&E staining from vehicle-treated CTPE tumours exhibited a higher mesenchymal characteristic, and CTPE cells are highly invasive, based on cell migration and wound healing assays ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). These results correlated with our earlier findings that prostate cancer cells exhibit a higher expression of mesenchymal markers such as *β*-catenin, snail and Slug; a hallmark for aggressive phenotype of prostate cancer ([@bib17]; [@bib55]). Similar molecular kinetics were found in CTPE cells and downregulation of mesenchymal genes by Pso were observed in both western blot and real time PCR analyses. Together, these results demonstrate that Pso effectively prevents CTPE tumour growth, suggesting the feasibility of preventing cadmium-induced prostate cancer by this natural compound. Pso is not only the compound that inhibits CTPE tumour formation, several dietary agents including ECGC ([@bib34]), Resveratrol ([@bib44]) Lycopene ([@bib22]) and diallyl disulphide ([@bib23]) effectively inhibit prostate cancer growth in both pre-clinical and clinical settings.

Confirming *in vitro* findings in animal studies suggest that inhibition of autophagy could be the mechanism of action for prevention of cadmium-induced prostate cancer. Inhibition of NF*κ*B and Plac8 suggests that these might be key players for the proliferation of CTPE cells. In conclusion, our results revealed an important insight in Plac8-mediated oncogenic autophagy-mediated cellular functions. Inhibition of the Plac8 signalling axis could be a potential biomarker or potential target for cadmium-exposed workers. However, more in depth studies may be required to understand the oncogenic function of Plac8 in prostate cancer.
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![**Psoralidin cytotoxicity in RWPE-1 and CTPE cells.** (upper panel) RWPE-1 and CTPE cells were treated with vehicle (DMSO; square) or the indicated concentrations of Pso (circle) for 24 h and cell viability determined. (middle panel) Cell proliferation was assessed by BrdU incorporation in CTPE cells treated with indicated concentrations of Pso. Data are expressed as mean±s.d. of two independent experiments done in triplicate. (lower panels) To assess anchorage-independent growth, CTPE (1 × 10^3^) cells were grown in soft agar with or without Pso for 10--15 days. Colonies were stained with crystal violet and counted manually. Student's *t*-test was used to calculate statistical significance between vehicle control and treatment at each concentration. \*\**P*\<0.01, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001.](bjc2017143f1){#fig1}

![**Psoralidin-induced autophagy in CTPE cells.** (upper left panel) Whole-cell lysates were prepared for western blot analysis to determine the expression levels of LC3IB and IIB, Plac8, LAMP1, Beclin, Atg-3, Atg-5, Atg-7, Atg-12 and Atg16L. *β*-actin was used as a loading control. (lower left panel) Total RNA was extracted and qRT-PCR performed to measure differences between the steady-state levels of expression of LC3B, Lamp1 and Plac8 from Pso-treated and -untreated CTPE cells. (upper right panel) Confocal microscopy was used with CTPE cells immunostained with Plac8, LAMP1 and LC3B antibodies. Autophagosome formation is marked by the presence of cytoplasmic puncta. (lower right panel) Localisation of Plac8 and LC3B; Cells treated in presence or absence of Pso and immunostained for Plac8 detection (green- Alexfluor 488) to visualise the overlap with LC3B (Red-alexafluor 594) which is shown as yellow. Student's *t*-test was used to calculate statistical significance between vehicle control and treatment at each concentration. \**P*\<0.05 and \*\*\**P*\<0.001. Densitometric analysis for western blots from two or three experiments are given in [Supplementary Information](#sup1){ref-type="supplementary-material"}.](bjc2017143f2){#fig2}

![**Psoralidin-induced apoptosis in CTPE cells.** CTPE cells were treated with 4 *μ*M Pso for 12 and 24 h and the levels of Bax, cleaved caspase-9, caspase-3 and PARP were measured by western blotting. Densitometric analysis of western blots from one, two or three experiments are given in [Supplementary Information](#sup1){ref-type="supplementary-material"}. *β*-actin was used as a loading control. CTPE cells were treated either with vehicle or Pso for 24 h and fixed with paraformaldehyde and permeabilised with sodium citrate and Triton X. DNA fragmentation was determined by TdT-mediated dUTP nick end labelling (TUNEL) (red channel). DAPI (blue channel) was used to locate the nuclei of the cell and numbers of cells were counted manually. Student's *t*-test was used to calculate statistical significance between vehicle control and Pso treatment. \*\**P*\<0.01](bjc2017143f3){#fig3}

![**Effects of Psoralidin on NF*κ*B signalling in CTPE cells.** (**A**) Western blot analyses of PI3K/NF*κ*B signalling in untreated and Pso-treated CTPE cells. Densitometric analysis of western blots from two or three experiments are given in [Supplementary Information](#sup1){ref-type="supplementary-material"}. (**B**) Nuclear extract was prepared from cells exposed to 4 *μ*M Pso for 24 h and untreated control cells. The levels of p65 in nuclear and cytoplasmic fractions were determined by western blot using Lamin A and *β*-actin as loading control, respectively. (**C**) Nuclear factions were subjected NF*κ*B p65 Transcription Factor Assay by EMSA analysis. (**D**) CTPE cells were untreated or exposed to 4 *μ*M Pso for 12 and 24 h. The levels of E-cadherin, *β*-catenin, Vimentin and MMP9 measured by western blot analysis with *β*-actin used as a loading control. (**E**) qRT-PCR was used to measure the steady-state mRNA levels of E-cadherin, *β*-catenin and MMP9 in untreated CTPE cells and those treated with Pso for 12 and 24 h. Densitometric analysis of western blots from two or three experiments are given in [Supplementary Information](#sup1){ref-type="supplementary-material"}. Student's *t*-test was used to calculate statistical significance between vehicle control (UT) and Pso-treated cells at each time point. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.](bjc2017143f4){#fig4}

![**Psoralidin inhibits CTPE xenografts tumour growth in nude mice.** CTPE cells in a 50-*μ*l (final volume) of phosphate-buffered saline and Matrigel (1 : 1) were subcutaneously injected into separate flanks of mice. Mice received vehicle (sesame oil; circles) or Pso (20 mg kg^−1^ Bw; squares) orally for 5 days per week up to 5 weeks. Tumour volumes (mm^3^) (upper panel) and mouse body weight (lower panel) were measured twice and once a week, respectively. Student's *t*-test was used to calculate statistical significance between Pso-treated and -untreated animals at each time point. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.](bjc2017143f5){#fig5}

![**(upper panel) Vehicle and Pso-treated tumour tissues were processed for H &E and immunohistochemical staining for Plac8, *β*-catenin, Ki-67 and RETIC.** Total of 300--400 cells were counted for positive cells and represented in [Supplementary Table 1](#sup1){ref-type="supplementary-material"} as average number of positive cells. (lower panel) qRT-PCR was performed to measure differences between the steady-state levels of expression of EMT markers in CTPE tumours from Pso-treated and -untreated animals. Student's *t*-test was used to calculate statistical significance between Pso-treated and -untreated tumours at each time point \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.](bjc2017143f6){#fig6}
